TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39043009
Drug: Treatment
Normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment
Study: 37535775
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection
Study: 36376887
Drug: Betaine 100
Normalized name: betaine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine 100 mg/kg/day
Study: 32251641
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg P2-VP8 vaccine
Study: 32251641
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg P2-VP8 vaccine
Study: 32251641
Drug: 90 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 μg P2-VP8 vaccine
Study: 35829751
Drug: Peak heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak heart rate prediction equation based on resting HR, presence of diabetes, physical dysfunction (gait speed < 1.0 m/s), and hypoalbuminemia (< 3.5 g/dL)
Study: 38937792
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment
Study: 33705168
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (Coping Cat)
Study: 33999939
Drug: 500 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg.kg‐1 BM sodium citrate ingested over 15 min
Study: 33999939
Drug: 500 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg.kg‐1 BM sodium citrate ingested over 45 min
Study: 35451391
Drug: 0.2 μg/(kg·h)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/(kg·h) of dexmedetomidine
Study: 35451391
Drug: 0.3 μg/(kg·h)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 μg/(kg·h) of dexmedetomidine
Study: 35451391
Drug: 0.4 μg/(kg·h)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 μg/(kg·h) of dexmedetomidine
Study: 35917052
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy (NET) for 4 months before surgery
Study: 35568822
Drug: Intratracheal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal dexmedetomidine (1 µg/kg) combined with 0.8% ropivacaine (40 mg)
Study: 35568822
Drug: Intratracheal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal dexmedetomidine (1 µg/kg)
Study: 36469298
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg/day for 28 days
Study: 36469298
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) through naso-duodenal tube, daily for seven days
Study: 39188940
Drug: Face-to-face treatment
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face treatment
Study: 34285005
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg once daily) + Exenatide QW (2 mg once weekly)
Study: 36811901
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg once daily)
Study: 34285005
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo tablet and sham injection)
Study: 32958014
Drug: AP 50
Normalized name: Mapap 500mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP 50 µmol/l
Study: 32958014
Drug: nab-P 5
Normalized name: Adenosine-5'P
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P 5 µmol/l + AP 10 µmol/l
Study: 32958014
Drug: nab-P 20
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P 20 mg/kg + AP 150 mg/kg
Study: 32958014
Drug: nab-P 18
Normalized name: 1,8-epoxy-p-menthane
DrugBank: Eucalyptol (DB03852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P 18 mg/kg + AP 150 mg/kg
Study: 32958014
Drug: nab-P 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P 16 mg/kg + AP 150 mg/kg
Study: 32958014
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of nab-P
Study: 35505441
Drug: 5‐mg/mL EGCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg/mL EGCG solution
Study: 35505441
Drug: Routine periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine periodontal therapy (Control)
Study: 37857291
Drug: Topiramate monotherapy
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate monotherapy
Study: 38555718
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2)
Study: 32788190
Drug: HPV vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine, Gardasil 9
Study: 32788190
Drug: Placebo hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo hepatitis A vaccine, Avaxim
Study: 35906874
Drug: Micronutrient-fortified balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-fortified balanced energy-protein (BEP) supplement and iron-folic acid (IFA) tablet
Study: 35906874
Drug: Iron-folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-folic acid (IFA) tablet
Study: 33779698
Drug: Ponesimod (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod (20 mg once daily)
Study: 36001711
Drug: Teriflunomide (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide (14 mg once daily)
Study: 34195864
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control arm)
Study: 33017565
Drug: Early Physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Physical Therapy (EPT)
Study: 34214479
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg, 4 × 100 mg film‐coated tablets per day for 26 weeks)
Study: 616382680
Drug: Gepotidacin 750
Normalized name: gepotidacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin 750 mg intravenous every 12 hours (q12h)
Study: 616382680
Drug: Gepotidacin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin 1,000 mg intravenous every 8 hours (q8h)
Study: 616382680
Drug: Gepotidacin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin 1,000 mg intravenous every 12 hours (q12h)
Study: 37349841
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg
Study: 33340245
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg
Study: 34980410
Drug: Human safety
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human safety claims (with 'Antibiotic‐free' and 'Pathogen‐ and zoonosis‐free')
Study: 36001840
Drug: Perioperative IV
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative IV TA alone and post‐operative oral TA (n=26)
Study: 36001840
Drug: Perioperative IV
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative IV TA plus 48 hours additional oral placebo (n=24)
Study: 34507703
Drug: LED phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LED phototherapy (630 nm and 940 nm) at a dose of 6 J/cm2, three times a week for 8 weeks
Study: 34507703
Drug: LED phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LED phototherapy (630 nm and 940 nm) at a dose of 8 J/cm2, three times a week for 8 weeks
Study: 34507703
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group) consisting of cleaning with physiological solution and alginate hydrogel dressing, daily for 8 weeks
Study: 35114151
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy only
Study: 34438361
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg saffron extract (affron®)
Study: 34460973
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg daily)
Study: 38421679
Drug: PRP injection
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP injection
Study: 34259904
Drug: Theophylline as
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline as an add-on to thrombolytic therapy
Study: 34259904
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as an add-on to thrombolytic therapy
Study: 33407269
Drug: 0.4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml/kg Formulaid™ (100 mg/kg of ARA and 50 mg/kg of DHA)
Study: 33407269
Drug: 0.4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml/kg MCT‐oil™ (medium chain triglycerides)
Study: 32111230
Drug: 4% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% albumin solution
Study: 35852528
Drug: Ringer acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer acetate solution
Study: 34444817
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of CoQ10 and 20 mg of NADH once daily
Study: 33728845
Drug: Psychiatric rehabilitation
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric rehabilitation along with standard pharmacological treatment
Study: 32412900
Drug: Bifidobacterium triple
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium triple viable capsule therapy
Study: 32412900
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-fat diet and Bifidobacterium triple viable capsule therapy
Study: 33892641
Drug: Galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab 120 mg/month (240 mg loading dose)
Study: 38683479
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg biweekly
Study: 34054112
Drug: risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone 4 mg
Study: 34932102
Drug: 60 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg RSVpreF
Study: 34932102
Drug: 120 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 µg RSVpreF
Study: 34932102
Drug: 240 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 µg RSVpreF
Study: 34508805
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy responders (n = 21)
Study: 34508805
Drug: Psychoeducation/supportive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation/supportive therapy responders (n = 6)
Study: 33892670
Drug: PDLASTA® (Pegfilgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDLASTA® (Pegfilgrastim) - single subcutaneous dose
Study: 33892670
Drug: PDGRASTIM® (Filgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDGRASTIM® (Filgrastim) - repeated six daily injections
Study: 35055694
Drug: 20% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glucose administered orally
Study: 36317518
Drug: Tegoprazan (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (50, 100, or 200 mg)
Study: 35191923
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy group (n=124): mechanical compression, intra-arrest transport to a cardiac center for ECPR and immediate invasive assessment and treatment.
Study: 35577874
Drug: Exercise Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Therapy (ET)
Study: 35760493
Drug: Open-label treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label treatment with Enterosgel
Study: 33300323
Drug: Conventional remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional remifentanil administration
Study: 33277980
Drug: Fosaprepitant dimeglumine
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosaprepitant dimeglumine (FD) intravenously administered (test group)
Study: 33277980
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (FD) intravenously administered (reference group)
Study: 35950949
Drug: Three-monthly viral
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-monthly viral load (VL) testing with additional drug exposure and drug resistance testing in case of viral rebound.
Study: 35950949
Drug: Three-monthly VL
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-monthly VL testing.
Study: 34794285
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) plus UDCA
Study: 38724947
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO)
Study: 35244287
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rFSH (0.5 IU/kg/d)
Study: 35244287
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose rFSH (1.1 IU/kg/d)
Study: 35244287
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rFSH (2.2 IU/kg/d)
Study: 35788868
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual control condition (n=110)
Study: 33637048
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) treatment
Study: 35943883
Drug: Riboflavin 50
Normalized name: riboflavin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 50 mg/d
Study: 33580297
Drug: β‐d‐glucan‐enriched mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐d‐glucan‐enriched mixture (10.4 g/day) from Lentinula edodes
Study: 33580297
Drug: Placebo incorporated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo incorporated in three different commercial creams
Study: 35997978
Drug: Edoxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (15 mg daily)
Study: 35821512
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT), 40 sessions daily
Study: 33021146
Drug: Application to
Normalized name: Embeline 0.05% Scalp Application Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application to track daily walking steps and interact via text messages with group members for 4 weeks
Study: 32822286
Drug: Binimetinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib (45 mg twice daily)
Study: 32822286
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice chemotherapy (PCC)
Study: 32854231
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment for 3 months
Study: 32302009
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin
Study: 34064493
Drug: Prednisone and
Normalized name: chloroprednisone and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone and antibiotherapy with surgical periodontal therapy
Study: 37805024
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (control group)
Study: 33885041
Drug: Pharmacologic prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic prophylaxis (low molecular weight heparin)
Study: 33885041
Drug: Pharmacologic prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic prophylaxis (unfractionated heparin)
Study: 34259402
Drug: Intradermal needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needling combined with heat-sensitive moxibustion
Study: 34259402
Drug: Opioids according
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioids according to the three-step analgesic method of WHO
Study: 34369941
Drug: IANB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB plus buccal infiltration (1.8 mL IANB + 1.8 mL buccal infiltration)
Study: 34369941
Drug: IANB (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB (3.6 mL)
Study: 34369941
Drug: IANB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB plus lingual infiltration (1.8 mL IANB + 1.8 mL lingual infiltration)
Study: 33687747
Drug: Molecularly guided
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly guided therapy
Study: 36330105
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (BIAsp 30)
Study: 37863366
Drug: Specialist Depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist Depression Service (SDS) offering collaborative treatment with cognitive behavioural therapy (CBT) and pharmacotherapy for 12 months
Study: 32996139
Drug: Antenatal exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal exercise program including pelvic floor muscle training (12-week standardized program with once weekly group classes and twice weekly home sessions)
Study: 34774360
Drug: Adjuvanted (AD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted (AD) vaccine
Study: 33295693
Drug: Conventional ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ACT (200 µg of inhaled salbutamol only)
Study: 37966817
Drug: Tafamidis 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis 80 mg
Study: 33070419
Drug: Tafamidis 20
Normalized name: TAFAMIDIS 20MG TAB UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis 20 mg
Study: 33220323
Drug: Pooled Tafamidis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled Tafamidis (80 mg and 20 mg)
Study: 32616003
Drug: 3.5 mm
Normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mm metallic screw (static implant)
Study: 32645234
Drug: Large volume
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volume transfusion (20 mL/kg)
Study: 32645234
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume transfusion (15 mL/kg)
Study: 38350047
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjuvant chemotherapy)
Study: 35338577
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy intervention for renal fatigue
Study: 34413064
Drug: Immediate endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate endovascular treatment
Study: 34413064
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who personally performed >100 endovascular treatments per year
Study: 35795564
Drug: Oil Palm
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil Palm Phenolics (OPP) 250 mg
Study: 33053048
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with Ringer's solution without FAW
Study: 36423442
Drug: TAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU plus up to 26 sessions of TwV therapy
Study: 34543267
Drug: Patient-centered integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered integrated chronic care model including treatment for hypertension, diabetes, and HIV.
Study: 34543267
Drug: Standard country-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard country-guided treatment (control group).
Study: 37815957
Drug: Traditional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional medicine
Study: 32884020
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg per day
Study: 36619724
Drug: HP eradication
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP eradication treatment
Study: 36619724
Drug: Standard NASH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard NASH treatment
Study: 32567544
Drug: Combination sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination sitagliptin and metformin
Study: 35468325
Drug: Tirzepatide 10
Normalized name: tirzepatide 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 10 mg and 15 mg
Study: 32734238
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution
Study: 35581902
Drug: Low-dose lobeglitazone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lobeglitazone (0.25 mg/day)
Study: 35581902
Drug: Standard-dose lobeglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose lobeglitazone (0.5 mg/day)
Study: 35089153
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavioral therapy (iCBT) for 5 weeks
Study: 38504157
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavioral therapy (iCBT)
Study: 34237697
Drug: Enhanced nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced nutritional supplement
Study: 32120787
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of water-soluble coenzyme Q10 (Q10Vital®) and collagen
Study: 39237149
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine